semaglutide glp 1 receptor agonist Rising Demand for GLP-1 Agonists Means an Increase in Patient Questions Semaglutide Shows Secondary Cardiovascular Prevention
Description
Moreover, liraglutide 3.0 mg (i.e., the dose level approved for weight management for this GLP-1 RA) in combination with lifestyle intervention markedly reduced the presence of visceral fat over a period of 40 weeks (Neeland et al., 2021)
Tresiba is insulin degludec, another long-acting basal insulin similar to Toujeo
Bear in mind that these drugs are not a first-line defense against mild weight gain
However, lets look a little past the convenience
They concluded that incretin-based medications did not correlate with an increased risk of acute pancreatitis or pancreatic cancer compared to other oral anti-diabetic agents, which remained consistent across drug classification and duration of use [29,55]
